Turmerones / GSH Cancer Research Results

TUR, Turmerones: Click to Expand ⟱
Features:

Turmerones — Turmerones are lipophilic volatile sesquiterpenes from turmeric rhizome oil, mainly ar-turmerone, α-turmerone, and β-turmerone. They are distinct from curcuminoids and should not be treated as curcumin synonyms. Formal classification: plant-derived volatile oil constituents / sesquiterpene ketones. Standard abbreviations include ATM or ar-T for aromatic turmerone, and α-TUR / β-TUR for α- and β-turmerone. Separate database product from whole turmeric or curcumin, because turmerones have different PK, BBB penetration, P-gp modulation, and apoptosis mechanisms from curcumin.

Primary mechanisms (ranked):

  1. ROS-linked mitochondrial and death-receptor apoptosis, especially reported for ar-turmerone in hepatocellular carcinoma and leukemia models.
  2. Growth suppression and programmed cell death in selected cancer cell lines, with strongest support in preclinical leukemia and hepatocellular carcinoma studies.
  3. Migration and invasion suppression in glioma models through cathepsin B and P27-related signaling.
  4. Inflammation and stress-pathway modulation, including NF-κB, JNK, p38 MAPK, COX-2, iNOS, cytokines, and MMP-related axes, mostly context-dependent.
  5. Curcumin bioavailability and transporter modulation, including altered Caco-2 transport and mixed P-gp effects depending on the turmerone isomer.

Bioavailability / PK relevance: Turmerones are more lipophilic than curcumin and are relevant as turmeric-oil constituents and as curcumin bioavailability modifiers. Reported animal PK suggests measurable systemic exposure, moderate oral bioavailability for major turmeric-oil constituents, and meaningful brain distribution. Human therapeutic PK for isolated turmerones remains insufficient.

In-vitro vs systemic exposure relevance: Many anticancer experiments use tens of μg/mL concentrations, which may exceed typical achievable free systemic exposure after ordinary turmeric intake. Turmeric oil or enriched turmerone formulations may increase exposure, but cancer-cell IC50 values should be treated as preclinical screening concentrations rather than clinically validated dosing targets.

Clinical evidence status: Preclinical. There is no strong cancer clinical-trial evidence for isolated turmerones. Human turmeric oil safety data and curcumin/turmeric-formulation trials do not establish turmerone-specific oncology efficacy. Recommended database status: add as a separate mechanistic/preclinical product, linked to turmeric oil and curcumin as related entries.

Turmerones Cancer Mechanism Table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Mitochondrial ROS apoptosis ↑ ROS, ↓ mitochondrial membrane potential, ↑ Bax, ↑ PUMA, ↑ cytochrome c release, ↑ caspase-9, ↑ caspase-3 Likely lower selectivity margin not fully established R/G Apoptosis induction Core ar-turmerone mechanism in hepatocellular carcinoma models; high concentration only; model-dependent
2 Death receptor apoptosis ↑ Fas, ↑ DR4, ↑ caspase-8, ↑ caspase-3 Insufficient direct comparison R/G Extrinsic apoptosis support Appears coupled to ROS and MAPK stress signaling rather than a fully independent primary trigger
3 JNK and ERK stress signaling ↑ JNK, ↑ ERK, ↑ pro-apoptotic signaling Context-dependent R/G Amplifies apoptosis Stress-kinase activation appears downstream of ROS in hepatocellular carcinoma models
4 Programmed cell death in leukemia ↑ DNA fragmentation, ↑ apoptotic morphology, ↓ viability Some selectivity reported versus selected non-target cells, but evidence remains limited G Cytotoxic apoptosis Older but relevant evidence supports ar-turmerone and related turmeric-oil constituents as apoptosis inducers in leukemia models
5 Glioma cathepsin B and P27 axis ↓ cathepsin B, ↓ P27 cleavage, ↓ proliferation, ↓ mobility Not well defined G Reduced proliferation and migration Potential CNS-oncology relevance because ar-turmerone is brain-penetrant; still preclinical
6 NF-κB inflammatory axis ↔/↓ NF-κB depending on model and stimulus ↓ NF-κB activation in inflammatory microglial models R/G Anti-inflammatory and context-dependent anticancer support curcuminoids suppress NF-κB more consistently than turmerones in some comparative studies
7 COX-2 iNOS MMP inflammatory mediators ↓ COX-2, ↓ MMP-related signaling (context-dependent) ↓ iNOS, ↓ COX-2, ↓ MMP-9 in activated microglia G Reduced inflammatory mediator output More relevant to inflammation, tumor microenvironment, and AD than direct tumor killing
8 P-gp and curcumin transport ↔ P-gp activity depending on isomer; ↑ curcumin cellular transport in Caco-2 model ↔ drug-transporter interaction risk R Bioavailability and drug-interaction modulation α-turmerone and ar-turmerone have different transporter effects; this is a key reason to keep turmerones separate from curcumin
9 Chemosensitization Possible ↑ intracellular exposure of co-administered compounds through transporter effects Possible altered exposure to normal tissues R/G Unproven adjunct potential Mechanistically plausible but not clinically established for oncology; not a strong chemosensitizer
10 Clinical Translation Constraint Preclinical activity often requires high μg/mL concentrations Oral oil safety appears better supported than isolated high-dose oncology use G Limits clinical confidence Major constraints are exposure, formulation, isomer composition, lack of isolated-turmerone cancer trials, and potential transporter-mediated interactions

P:0–30 min R:30 min–3 hr G:>3 hr



GSH, Glutathione: Click to Expand ⟱
Source:
Type:
Glutathione (GSH) is a thiol antioxidant that scavenges reactive oxygen species (ROS), resulting in the formation of oxidized glutathione (GSSG). Decreased amounts of GSH and a decreased GSH/GSSG ratio in tissues are biomarkers of oxidative stress.
Glutathione is a powerful antioxidant found in every cell of the body, composed of three amino acids: cysteine, glutamine, and glycine. It plays a crucial role in protecting cells from oxidative stress, detoxifying harmful substances, and supporting the immune system.
cancer cells can have elevated levels of glutathione, which may help them survive in the oxidative environment created by the immune response and chemotherapy. This can make cancer cells more resistant to treatment.
While glutathione can be obtained from certain foods (like fruits, vegetables, and meats), its absorption from supplements is debated. Some people take N-acetylcysteine (NAC) or other precursors to boost glutathione levels, but the effects on cancer prevention or treatment are still being studied.
Depleting glutathione (GSH) to raise reactive oxygen species (ROS) is a strategy that has been explored in cancer research and therapy.
Many cancer cells have altered redox states and may rely on GSH to survive. Increasing ROS levels can induce stress in these cells, potentially leading to cell death.
Certain drugs and compounds can deplete GSH levels. For example, agents like buthionine sulfoximine (BSO) inhibit the synthesis of GSH, leading to its depletion.
Cancer cells tend to exhibit higher levels of intracellular GSH, possibly as an adaptive response to a higher metabolism and thus higher steady-state levels of reactive oxygen species (ROS).

"...intracellular glutathione (GSH) exhibits an astounding antioxidant activity in scavenging reactive oxygen species (ROS)..."
"Cancer cells have a high level of GSH compared to normal cells."
"...cancer cells are affluent with high antioxidant levels, especially with GSH, whose appearance at an elevated concentration of ∼10 mM (10 times less in normal cells) detoxifies the cancer cells." "Therefore, GSH depletion can be assumed to be the key strategy to amplify the oxidative stress in cancer cells, enhancing the destruction of cancer cells by fruitful cancer therapy."

The loss of GSH is broadly known to be directly related to the apoptosis progression.


Scientific Papers found: Click to Expand⟱
6453- TUR,    Pharmacological Profile, Bioactivities, and Safety of Turmeric Oil
- Review, Var, NA - Review, AD, NA - Review, Park, NA
*Dose↝, *BioEnh↑, *BBB↑, *ROS↓, *GSH↑, *SOD↑, *GSR↑, *NO↓, *P450↓, OS↑, TumCG↓, *GutMicro↑, *Pain↓, *neuroP↑, *AChE↓, *BDNF↑, *Bacteria↓, *AntiFungal↑, *toxicity↓,
6458- TUR,    Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism
- in-vitro, lymphoma, U937
ROS∅, GSH∅,
6460- TUR,  CUR,    Neuroprotective Effect of Turmeric Extract in Combination with Its Essential Oil and Enhanced Brain Bioavailability in an Animal Model
- in-vivo, AD, NA
*memory↑, *lipid-P↓, *GSH↑, *AChE↑, *Catalase↑, *BioAv↑, *P-gp↓, *BioAv↑, *SOD↑, *BBB↑, *ROS↓,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

GSH∅, 1,   ROS∅, 1,  

Proliferation, Differentiation & Cell State

TumCG↓, 1,  

Functional Outcomes

OS↑, 1,  
Total Targets: 4

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

Catalase↑, 1,   GSH↑, 2,   GSR↑, 1,   lipid-P↓, 1,   ROS↓, 2,   SOD↑, 2,  

Angiogenesis & Vasculature

NO↓, 1,  

Barriers & Transport

BBB↑, 2,   P-gp↓, 1,  

Synaptic & Neurotransmission

AChE↓, 1,   AChE↑, 1,   BDNF↑, 1,  

Drug Metabolism & Resistance

BioAv↑, 2,   BioEnh↑, 1,   Dose↝, 1,   P450↓, 1,  

Clinical Biomarkers

GutMicro↑, 1,  

Functional Outcomes

memory↑, 1,   neuroP↑, 1,   Pain↓, 1,   toxicity↓, 1,  

Infection & Microbiome

AntiFungal↑, 1,   Bacteria↓, 1,  
Total Targets: 23

Scientific Paper Hit Count for: GSH, Glutathione
3 Turmerones
1 Curcumin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:408  Target#:137  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page